Skip to main content
Evidence Snapshot

Aromatase

CHEMBL1978 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:24:31Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1978
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Aromatase as ChEMBL target CHEMBL1978, mapped to UniProt P11511. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Aromatase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1978
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P11511
Aromatase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Aromatase matters

As of 2026-09-13

Aromatase is reviewed as Aromatase (UniProt P11511); Aromatase shows approved-linked disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block.; 4 linked drugs keep this evidence frame grounded.; the current evidence base includes 21 approved drugs, 3993 compounds, and 717 assays, with lead potency reaching pChEMBL 11.0.

Disease context
breast cancer

Aromatase shows approved-linked disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block. 4 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include AMINOGLUTETHIMIDE, ANASTROZOLE, EXEMESTANE.

Start review with breast cancer because it currently carries approved-linked support. Linked drugs include AMINOGLUTETHIMIDE, ANASTROZOLE, EXEMESTANE, LETROZOLE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 4 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 21 approved drugs, 3993 compounds, and 717 assays for this target. The dominant activity type is IC50. CHEMBL4632445 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL4632445 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine
21 approved pChEMBL 11.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Aromatase matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P11511, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why breast cancer is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

3993
Total Compounds
717
Total Assays
21
Approved Drugs
IC50: 4409.0, KI: 641.0, EC50: 14.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4632445
 11.0 IC50 —
No preferred name
CHEMBL4639677
 11.0 IC50 —
No preferred name
CHEMBL1672978
 10.8 IC50 —
No preferred name
CHEMBL1672980
 10.8 IC50 —
No preferred name
CHEMBL1672979
 10.7 IC50 —

Approved Drugs

Structure Compound First Approval
OSILODROSTAT
CHEMBL3099695
 2020
EXEMESTANE
CHEMBL1200374
 1999
LETROZOLE
CHEMBL1444
 1997
ANASTROZOLE
CHEMBL1399
 1995
KETOCONAZOLE
CHEMBL157101
 1981
AMINOGLUTETHIMIDE
CHEMBL488
 1980
CLOTRIMAZOLE
CHEMBL104
 1975
MICONAZOLE
CHEMBL91
 1974
TESTOSTERONE
CHEMBL386630
 1972
FLUOROURACIL
CHEMBL185
 1962
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:24:31Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1978